[go: up one dir, main page]

CU20110232A7 - Inyección de diacetato de ipamorelin y soluciones de la infusión - Google Patents

Inyección de diacetato de ipamorelin y soluciones de la infusión

Info

Publication number
CU20110232A7
CU20110232A7 CU20110232A CU20110232A CU20110232A7 CU 20110232 A7 CU20110232 A7 CU 20110232A7 CU 20110232 A CU20110232 A CU 20110232A CU 20110232 A CU20110232 A CU 20110232A CU 20110232 A7 CU20110232 A7 CU 20110232A7
Authority
CU
Cuba
Prior art keywords
ipamorelin
injection
infusion solutions
diacetate
acetic acid
Prior art date
Application number
CU20110232A
Other languages
English (en)
Inventor
Roccardo Braglia
Helle Weibel
Daniel Beidler
Rubio Silvina Garcia
Original Assignee
Helsinn Therapeutics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110232(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Therapeutics Us Inc filed Critical Helsinn Therapeutics Us Inc
Publication of CU20110232A7 publication Critical patent/CU20110232A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Soluciones de la inyección y de la infusión de ipamorelin que tienen la siguiente composición: a) ipamorelin solubilizado por aproximadamente dos equivalentes molares de ácido acético (diacetato de ipamorelin), en una cantidad a partir de 0.001 al 20%, basada enb el peso de la base libre del ipamorelin; b) un exceso molar de ácido, preferiblemente ácido acético, en cantidad suficiente para dar un pH de por lo menos 3 y menos de 7; c) opcionalmente a partir de 0.1 al 30% de una o más ayudas de la formulación; y d) agua q.s. al 100% todos los porcentajes basados en el peso total de la solución.
CU20110232A 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión CU20110232A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659509P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
CU20110232A7 true CU20110232A7 (es) 2012-06-21

Family

ID=42272260

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110232A CU20110232A7 (es) 2009-06-12 2011-12-12 Inyección de diacetato de ipamorelin y soluciones de la infusión

Country Status (24)

Country Link
US (1) US20100317581A1 (es)
EP (1) EP2440180B1 (es)
JP (1) JP2012529510A (es)
KR (1) KR20120030530A (es)
CN (1) CN102481251A (es)
AU (1) AU2010259102B2 (es)
BR (1) BRPI1012931A2 (es)
CA (1) CA2765233A1 (es)
CL (1) CL2011003131A1 (es)
CO (1) CO6470880A2 (es)
CR (1) CR20110618A (es)
CU (1) CU20110232A7 (es)
DO (1) DOP2011000383A (es)
EA (1) EA201270011A1 (es)
EC (1) ECSP11011516A (es)
GT (1) GT201100318A (es)
MX (1) MX2011013113A (es)
NI (1) NI201100212A (es)
NZ (1) NZ596641A (es)
PE (1) PE20121064A1 (es)
SG (1) SG176717A1 (es)
TW (1) TW201106961A (es)
UA (1) UA104762C2 (es)
WO (1) WO2010144265A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6193017B2 (ja) * 2013-06-28 2017-09-06 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
WO2015145860A1 (ja) 2014-03-28 2015-10-01 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115635B1 (ro) * 1993-12-23 2000-04-28 Novo Nordisk As Peptida cu proprietati de eliberare a hormonului de crestere si compozitie farmaceutica cu aceasta
AU4911500A (en) * 1999-06-04 2000-12-28 Novo Nordisk A/S Compositions for the treatment of the catabolic state of prolonged critical illness
JP4874989B2 (ja) * 2004-11-22 2012-02-15 ノヴォ ノルディスク アー/エス 可溶性で安定なインスリン含有調合物
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물
EP2129401B8 (en) * 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
AU2008341160A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну

Also Published As

Publication number Publication date
EP2440180A2 (en) 2012-04-18
AU2010259102B2 (en) 2013-09-12
NI201100212A (es) 2012-04-11
CN102481251A (zh) 2012-05-30
US20100317581A1 (en) 2010-12-16
KR20120030530A (ko) 2012-03-28
CA2765233A1 (en) 2010-12-16
NZ596641A (en) 2013-12-20
EP2440180B1 (en) 2014-08-27
JP2012529510A (ja) 2012-11-22
SG176717A1 (en) 2012-01-30
TW201106961A (en) 2011-03-01
PE20121064A1 (es) 2012-09-03
MX2011013113A (es) 2012-02-21
AU2010259102A1 (en) 2012-01-12
UA104762C2 (ru) 2014-03-11
CO6470880A2 (es) 2012-06-29
EA201270011A1 (ru) 2012-05-30
CL2011003131A1 (es) 2012-08-17
GT201100318A (es) 2014-10-13
DOP2011000383A (es) 2012-05-31
WO2010144265A2 (en) 2010-12-16
ECSP11011516A (es) 2012-03-30
WO2010144265A3 (en) 2011-11-24
BRPI1012931A2 (pt) 2018-01-30
CR20110618A (es) 2012-03-02

Similar Documents

Publication Publication Date Title
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
UA105229C2 (uk) Фармацевтичний склад
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
AR081983A1 (es) Articulo de dosis unitaria soluble que comprende un polimero cationico
UA114351C2 (uk) Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
BR112014017169A2 (pt) máquina de bebidas com módulo removível
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
EA201201298A1 (ru) Фунгицидные композиции, содержащие фосфорастворимый микроорганизм и фунгицидно активное соединение
MY151295A (en) Pyrimidyl indoline compound
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
MX2013005172A (es) Producto de cuidado oral y metodos de uso y fabricacion de los mismos.
TR200806298A2 (tr) Farmasötik formülasyon
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
IN2012DN00765A (es)
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
AR086395A1 (es) Envase para el tratamiento de patologias
WO2014020405A8 (en) Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
CO6310996A2 (es) Composicion fungicida que contiene un compuesto de imidazol en combinación con polioxinas
CU20110232A7 (es) Inyección de diacetato de ipamorelin y soluciones de la infusión
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
CO6270205A2 (es) Formulacion que contiene un compuesto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo
JP2011093891A5 (es)
RU2010126053A (ru) Применение аналогов соматостатина при менингиоме
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.